Cervomed Inc (CRVO) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cervomed Inc   (NASDAQ: CRVO)


Cervomed Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Cervomed Inc 's ROA in the first quarter of 2026?
Cervomed Inc recorded a cumulative net loss of $-30 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -112.62%.

However, within the Healthcare sector 760 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4309, from total ROA ranking in the fourth quarter of 2025 at 4897.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change -60.82 % -46.89 % -37.38 % -29.65 % 382.37 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -30 -27 -26 -23 -19
Return On Assets (TTM) -112.62 % -82.88 % -68.07 % -53.64 % -40.44 %
CRVO's Total Ranking # 4309 # 4897 # 4199 # 4112 # 4028
Total Assets (TTM) in million 15 23 31 38 39
Seq. Total Assets Change -33.94 % -25.26 % -19.62 % -1.29 % -10.45 %
Seq. Net Income Change - - - - -

CRVO's 5 Years Annual ROA >> Back to CRVO Management Effectiveness >> Compare CRVO ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 352
Sector # 761
Overall # 4267

Return On Assets Statistics
High Average Low
7.49 %
-46.93 %
-112.62 %
(Sep 30 2023)   (Mar 31 2026)



  News about Cervomed Inc Return on Assets ROA

CervoMed's Appointment of William Elder as CFO Bolsters Future Prospects for Neurologic Disorders Treatment

CervoMed s Strategic Appointment of William Elder as CFO Signals Promising Future for Neurologic Disorders Treatment
CervoMed Inc., a renowned clinical stage company dedicated to the development of treatments for age-related neurologic disorders, has recently announced a significant addition to its leadership team. William (Bill) Elder, currently serving as General Counsel and Corporate Secretary, will assume the role of Chief Financial Officer (CFO) effective June 1, 2024. This decision comes as a part of CervoMed s ongoing efforts to strengthen its financial management and drive further growth in the sector.
Elder s appointment as CFO is backed by his extensive experience in the field. Having served CervoMed and its predecessor, EIP Pharma, since September 2022, William Tanner, the outgoing CFO, will continue to support the company as a consultant during the transition. This seamless handover ensures the continuity of strategic financial decisions while allowing Elder to bring his unique expertise to the table.

CervoMed: Revolutionizing Healthcare with $149 Million in Major Funding

CervoMed Secures Major Funding with Leading Healthcare Investors

In a recent development, CervoMed, a prominent player in the healthcare sector, has announced its successful completion of a private placement financing round, raising $149.4 million. This impressive investment comes from a group of esteemed investors including RA Capital Management, Armistice Capital, Special Situations Funds, and Soleus Capital. The funding secured by CervoMed is expected to foster significant advancements in the company s innovative healthcare solutions and drive its market expansion.
Market Prospects and Investor Confidence:
This substantial private placement financing round indicates the promising growth prospects of the healthcare industry. The healthcare sector has always been a lucrative investment opportunity due to its resilience and relevance. Investors are recognizing the increasing demand for healthcare solutions and the potential for substantial returns on investment. Consequently, these leading investors have shown their confidence in CervoMed s innovative offerings, signaling a positive outlook for the company s future trajectory.
RA Capital Management s Strategic Investment:
RA Capital Management, a well-established healthcare investment firm, has chosen to invest in CervoMed, further reinforcing the company s potential. RA Capital Management has built a strong reputation for supporting innovative healthcare companies that have the potential to transform patient outcomes. By bringing their expertise and financial backing to CervoMed, RA Capital Management validates the credibility and viability of the company s solutions, augmenting its market value.



Financial Statements
Cervomed Inc 's Assets $ 15 million CRVO's Balance sheet
Cervomed Inc 's Income $ -8 million Quarterly CRVO's Income Statement
CRVO's Income by Division See CRVO's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023
FY
FY
Y / Y Total Assets Change -46.89 % 332.01 % -58.97 % -43.18 % 133.2 %
Total Assets in million 23 43 10 24 43
Y / Y Net Income Change - - - - -
Net Income in million -27 -16 -2 0 0
Annual Return On Assets -117.86 % -37.81 % -21.78 % - -

CRVO's 5 Years Annual ROA >> Back to CRVO Management Effectiveness >> Compare CRVO ROA to its Competitors



More Return On Assets Ratios
CRVO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CRVO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CRVO's Competitors
Subscribers only: Roa for Cervomed Inc 's Suppliers
Subscribers only: Return On Assets for CRVO's Customers

You may also want to know
CRVO's Roi CRVO's Inventory Turnover Ratio CRVO's Growth Rates CRVO's Dividend Comparisons
CRVO's Profitability Ratios CRVO's Asset Turnover Ratio CRVO's Dividend Growth
CRVO's Roe CRVO's Valuation Ratios CRVO's Financial Strength Ratios CRVO's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA

Date modified: 2026-09-26T07:14:03+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.